Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: lexi2004 who wrote (175519)	7/8/2008 4:59:18 PM
From: PJr	Read Replies (1) \| Respond to of 208838

Lexi, Looks like the news that must have leaked on HEB last week finally hit the wires today. Nice little bump today. I thought it was looking a little "wired" last week. PHILADELPHIA, July 8, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB - News) today reported that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for Ampligen(r), an experimental therapeutic, to treat Chronic Fatigue Syndrome (CFS), originally submitted in October 2007. Hemispherx is seeking marketing approval for the first-ever treatment for CFS. At present, only supportive, symptom-based care is available for CFS patients. The NDA for Ampligen(r), whose chemical designation is poly I : poly C12U, is also the first ever accepted for review by the FDA for systemic use of a toll-like receptor (TLR) therapy to treat any condition. Pat